Icon Close

Seagen is now part of Pfizer!  Please visit Pfizer.com for more information.

For US residents only.

Seagen is now part of Pfizer! This page will no longer be updated, but you can visit Pfizer.com for more information on this change, or visit the "Executive Leadership” page on Pfizer.com
Who We Are


Our leadership team brings diverse experience in research, clinical development, business operations, and patient care to Seagen. Their expertise and guidance are critical to advancing our mission to make a meaningful difference in cancer care.

David Epstein Color

David R. Epstein

Chief Executive Officer

Leadership Team

Seagen CMO - Roger Dansey, M.D.

Roger Dansey, M.D.

President, Research and Development

Seagen CTO - Vaughn Himes, Ph.D.

Vaughn Himes, Ph.D.

Chief Technical Officer

Seagen EVP Corporate Development - Natasha Hernday

Natasha Hernday

Chief Business Officer

Seagen CFO - Todd Simpson

Todd Simpson

Chief Financial Officer

Lee Heeson

Lee Heeson

Executive Vice President, Commercial International

Chief Legal Officer - Jean Liu, J.D.

Jean Liu, J.D.

Chief Legal Officer

Seagen EVP Commercial U.S. - Charles (Chip) Romp

Charles (Chip) Romp

Executive Vice President, Commercial U.S.

Peggy Pinkston

Peggy Pinkston

Chief Human Resources Officer

Sherry Pudloski

Sherry Pudloski

Senior Vice President, Chief Corporate Affairs Officer

Lu Chen

Lu Chen

Executive Director, Global Strategic Initiatives

William Compton

William Compton

Senior Vice President, Global Information Technology, CIO


Felix Baker, Ph.D.

Felix Baker

Dr. Baker has served on the Board of Directors for Seagen since July 2003, as our lead independent director since February 2005, and was appointed Chair of the Board in May 2022. He is also the founder of Baker Bros. Advisors LP, an advisory firm focused on investments in life science and biotechnology companies. As a board member and investor in many successful biotechnology companies, Dr. Baker’s experience and vision in investment and company building adds significant value to Seagen’s strategy.  

Dr. Baker holds a B.S. and a Ph.D. in Immunology from Stanford University, where he also completed two years of medical school. He serves as a member of the board of directors of Kiniksa Pharmaceuticals, Ltd., Kodiak Sciences Inc. and IGM Biosciences, Inc.

David R. Epstein

David Epstein BW

Mr. Epstein joined Seagen as Chief Executive Officer and a member of the Board of Directors in 2022, bringing more than 30 years of drug development, deal making, commercialization and people leadership experience on a global scale. Prior to Seagen, he was executive partner at Flagship Pioneering. From 2010 to mid-2016 he served as Chief Executive Officer of Novartis Pharmaceuticals, a division of Novartis AG.

Previously, David started and led Novartis’ Oncology and Molecular Diagnostic units. Over the course of his career, he led the development and commercialization of over 30 new molecular entities, including major breakthroughs such as Glivec, Tasigna, Gilenya, Cosentyx and Entresto.

Mr. Epstein holds a B.S. Degree in Pharmacy from Rutgers University College of Pharmacy and an MBA in Finance and Marketing from the Columbia University Graduate School of Business. He serves as a member of the board of directors for OPY Acquisition Corp. I.

David Gryska

David Gryska

Mr. Gryska joined our Board of Directors in March 2005. With many years of experience as a senior financial executive at life sciences and biotechnology companies, he brings expertise in financing, global expansion, and other strategic transactions to our board. Mr. Gryska is the chair of our Audit Committee, utilizing his extensive knowledge of accounting principles, financial reporting rules and regulations, tax compliance, and financial reporting processes at publicly traded corporations.  

Throughout his career, Mr. Gryska served as a Chief Financial Officer at Incyte Corporation, Celgene Corporation, Scios Inc., and Cardiac Pathways Corporation.

Mr. Gryska holds an M.B.A. from Golden Gate University and a B.A. in Accounting and Finance from Loyola University. He serves as a member of the board of directors of Forte Biosciences, Inc. and Mind Medicine (MindMed) Inc.

Ted Love, M.D.

Ted Love

Dr. Love joined our Board of Directors in August 2020. With more than two decades of leadership and management experience in the pharmaceutical industry, in addition to prior experience as a practicing physician, Dr. Love brings both strong business expertise and knowledge of patient perspectives to our Board of Directors.

Dr. Love was most recently the President and Chief Executive Officer of Global Blood Therapeutics, Inc. until its acquisition by Pfizer in 2022. Previously, he was Executive Vice President, Research and Development and Technical Operations at Onyx Pharmaceuticals, Inc.

Dr. Love holds a B.A. in Molecular Biology from Haverford College and an M.D. from Yale Medical School. Dr. Love also serves on the board of Royalty Pharma plc and Structure Therapeutics Inc.

John Orwin

John Orwin

Mr.  Orwin  joined the Seagen Board of Directors in January 2014. With many years of experience as a senior executive at leading pharmaceutical and biotechnology companies, he brings a strong understanding of the industry and the challenges we must meet to continue developing and commercializing product candidates.  

Mr. Orwin is the President and Chief Executive Officer of Atreca, Inc. Previously, he was the Chief Executive Officer of Relypsa, Inc., now an affiliate of Vifor Pharma AG. Mr. Orwin also held multiple leadership roles at Affymax, Inc., including Chief Executive Officer, President, and Chief Operating Officer. Earlier in his career, he led the BioOncology Business Unit at Genentech, Inc. and was the Franchise Vice President of Tibotec Therapeutics at Johnson & Johnson.  

Mr. Orwin holds an M.B.A. from the Stern School of Business at New York University and a B.A. in Economics from Rutgers University. He serves as Chairman of the Board for AnaptysBio, Inc. and as a member of the board of directors for Atreca, Inc. and Travere Therapeutics, Inc.

Alpna Seth, Ph.D.

Alpna Seth

Dr. Seth joined our Board of Directors in March 2018. With more than 20 years of global experience in the biotechnology industry, she brings a breadth of expertise in drug development, commercialization, and international operations to Seagen.  

Dr. Seth was most recently the Chief Executive Officer and President of Nura Bio, a biopharmaceutical company focused on the discovery of novel neuroprotective drugs. Previously, she was Chief Operating Officer of Vir Biotechnology, Inc. and the Senior Vice President and Global Head of the Biosimilars Global Business Unit at Biogen Inc. Before joining Biogen, Dr. Seth was a management consultant in the healthcare industry.  

Dr. Seth earned her Ph.D. in Biochemistry and Molecular Biology from the University of Massachusetts Medical School and completed post-doctoral research at Harvard University in Immunology and Structural Biology. She is a graduate of Harvard Business School’s Advanced Management Program (AMP) and has served as a guest lecturer at Harvard Business School and Harvard Medical School. Dr. Seth serves as a member of the board of directors for Bio-Techne Corporation, Dr. Reddy's Laboratories Limited and Keros Therapeutics, Inc.

Nancy Simonian, M.D.

Nancy Simonian

Dr. Simonian is a seasoned senior executive in biotechnology who joined the Seagen Board of Directors in March 2012. She possesses a deep understanding of the biotechnology industry and the development and commercialization of product candidates. As a physician, Dr. Simonian also brings important insight into patient perspectives to our Board of Directors.  

Dr. Simonian is the Chief Executive Officer of Syros Pharmaceuticals, Inc. Previously, she was the Chief Medical Officer at Millennium Pharmaceuticals, Inc. and the Vice President of Clinical Development at Biogen. 

Dr. Simonian holds an M.D. from the University of Pennsylvania Medical School and a B.A. in Biology from Princeton University. She serves as a member of the board of directors for Syros Pharmaceuticals, Inc.

Sandra M. Swain, M.D.


Dr. Swain has served on the board of Seagen since November 2022. With over thirty years of experience in clinical trial design, implementation, execution and publication of major international trials in breast cancer, she brings a critical perspective to our development of targeted oncology therapies.  

Dr. Swain is the Associate Dean for Research Development and Professor of Medicine at the Georgetown University Medical Center and the Vice President of Genetic Medicine for MedStar Health. Previously, she held leadership roles at the National Cancer Institute (NCI), National Institutes of Health (NIH) and the Washington Cancer Institute at MedStar Washington Hospital Center. Dr. Swain is a fellow of the American College of Physicians and the American Society of Clinical Oncology (ASCO). She has served on ASCO’s board of directors and is a past president (2012-2013). She currently serves on the Conquer Cancer Foundation Board of ASCO and chairs the Women Who Conquer Cancer committee. Dr. Swain has also published over 325 articles, including many regarding clinical trials in breast cancer. 

Dr. Swain holds an M.D. from the University of Florida and a B.A. in Chemistry from the University of North Carolina. She completed her fellowship in medical oncology at the NCI, NIH.

Daniel Welch

Daniel Welch

Mr. Welch has served on the Board of Directors for Seagen since June 2007. With a background in global commercial development and experience as a senior executive at biotechnology companies, he contributes invaluable strategic insight to our senior management and Board of Directors.  

Previously, Mr. Welch was an Executive Partner at Sofinnova Ventures and the Chairman and Chief Executive Officer of two publicly traded biotechnology companies, InterMune, Inc. and Triangle Pharmaceuticals, Inc. 

Mr. Welch holds an M.B.A. from the University of North Carolina and a B.A. from the University of Miami. He serves as Chairman of the Board for Ultragenyx Pharmaceutical Inc., Nuvation Bio Inc., and Structure Therapeutics Inc.